A novel rat fibrosarcoma cell line from transformed bone marrow-derived mesenchymal stem cells with maintained in vitro and in vivo stemness properties

Experimental Cell Research

Volumn 352, Issue 2, 2017, Pages 218-224

  Wang, Meng Yu ^a   Nestvold, Janne ^b   Rekdal, Øystein ^c   Kvalheim, Gunnar ^a   Fodstad, Øystein ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c UNIVERSITY OF TROMSØ   (Norway)

Author keywords

Cancer stem cells; Fibrosarcoma tumor model; Mesenchymal stem cells; Side population; Transformed cell line

Indexed keywords

THY 1 ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW DERIVED MESENCHYMAL STEM CELL; CARCINOGENICITY; CELL CULTURE; CELL POPULATION; CELL PROLIFERATION; CHROMOSOME ANALYSIS; CONTROLLED STUDY; FIBROSARCOMA CELL LINE; IMMUNOCOMPETENCE; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TRANSFORMED CELL; ANIMAL; BONE MARROW CELL; CANCER STEM CELL; CELL CULTURE TECHNIQUE; CELL TRANSFORMATION; CYTOLOGY; DRUG SCREENING; FIBROSARCOMA; MESENCHYMAL STROMA CELL; MOUSE; NUDE MOUSE; NUDE RAT; PATHOLOGY; PROCEDURES; TUMOR CELL LINE;

ANIMALS; BONE MARROW CELLS; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; FIBROSARCOMA; MESENCHYMAL STROMAL CELLS; MICE; MICE, NUDE; NEOPLASTIC STEM CELLS; RATS; RATS, NUDE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85012941533     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2017.02.005     Document Type: Article

References (41)

1. [1] Ld.S., Meirelles, Chagastelles, P.C., Nardi, N.B., Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J. Cell Sci. 119:11 (2006), 2204–2213.
2. [2] Dominici, M.L.B.K., Mueller, I., Slaper-Cortenbach, I., Marini, F., Krause, D., Deans, R., Keating, A., Prockop, Dj, Horwitz, E., Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8:4 (2006), 315–317.
3. [3] García-Castro, J., Trigueros, C., Madrenas, J., Pérez-Simón, J.A., Rodriguez, R., Menendez, P., Mesenchymal stem cells and their use as cell replacement therapy and disease modelling tool. J. Cell. Mol. Med. 12:6b (2008), 2552–2565.
4. [4] Ankrum, J.A., Ong, J.F., Karp, J.M., Mesenchymal stem cells: immune evasive, not immune privileged. Nat. Biotech. 32:3 (2014), 252–260.
5. [5] Naka, N.T.S., Araki, N., Miwa, T., Hashimoto, N., Yoshioka, K., Joyama, S., Hamada, K., Tsukamoto, Y., Tomita, Y., Ueda, T., Yoshikawa, H., Itoh, K., Synovial sarcoma is a stem cell malignancy. Stem Cells 28:7 (2010), 1119–1131.
6. [6] Tolar, J.N.A., Osborn, M.J., Panoskaltsis Mortari, A., McElmurry, R.T., Bell, S., Xia, L., Zhou, N., Riddle, M., Schroeder, T.M., Westendorf, J.J., McIvor, R.S., Hogendoorn, P.C., Szuhai, K., Oseth, L., Hirsch, B., Yant, S.R., Kay, M.A., Peister, A., Prockop, D.J., Fibbe, W.E., Blazar, B.R., Sarcoma derived from cultured mesenchymal stem cells. Stem Cells 25:2 (2007), 371–379.
7. [7] Choi, J., Curtis, S.J., Roy, D.M., Flesken-Nikitin, A., Nikitin, A.Y., Local mesenchymal stem/progenitor cells are a preferential target for initiation of adult soft tissue sarcomas associated with p53 and Rb deficiency. Am. J. Pathol. 177:5 (2010), 2645–2658.
8. [8] Mohseny, A.B.H.P., Concise review: mesenchymal tumors: when stem cells go mad. Stem Cells 29:3 (2011), 397–403.
9. [9] Rodriguez, R., Rubio, R., Menendez, P., Modeling sarcomagenesis using multipotent mesenchymal stem cells. Cell Res. 22:1 (2012), 62–77.
10. [10] Mohseny, A.B., Szuhai, K., Romeo, S., Buddingh, E.P., Briaire-de Bruijn, I., de Jong, D., van Pel, M., Cleton-Jansen, A.M., Hogendoorn, P.C., Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2. J. Pathol. 219:3 (2009), 294–305.
11. [11] Miura, M.M.Y., Padilla-Nash, H.M., Molinolo, A.A., Fu, B., Patel, V., Seo, B.M., Sonoyama, W., Zheng, J.J., Baker, C.C., Chen, W., Ried, T., Shi, S., Accumulated chromosomal instability in murine bone marrow mesenchymal stem cells leads to malignant transformation. Stem Cells 24:4 (2006), 1095–1103.
12. [12] Bernardo, M.E., Zaffaroni, N., Novara, F., Cometa, A.M., Avanzini, M.A., Moretta, A., et al. Human bone marrow–derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms. Cancer Res. 67:19 (2007), 9142–9149.
13. [13] Torsvik, A., Rosland, G.V., Molven, A., Immervoll, H., McCormack, E., Lønning, P.E., Primon, M., Sobala, E., Tonn, J.C., Goldbrunner, R., Schichor, C., Mysliwietz, J., Lah, T.T., Motaln, H., Knappskog, S., Bjerkvig, R., Spontaneous malignant transformation of human mesenchymal stem cells reflects cross-contamination: putting the research field on track - letter. Cancer Res. 70:15 (2010), 6393–6396.
14. [14] Peto, R., Roe, F.J., Lee, P.N., Levy, L., Clack, J., Cancer and ageing in mice and men. Br. J. Cancer 32:4 (1975), 411–426.
15. [15] Caulin, A.F., Maley, C.C., Peto's Paradox: evolution's prescription for cancer prevention. Trends Ecol. Evol. 26:4 (2011), 175–182.
16. [16] Funes, J.M., Quintero, M., Henderson, S., Martinez, D., Qureshi, U., Westwood, C., et al. Transformation of human mesenchymal stem cells increases their dependency on oxidative phosphorylation for energy production. Proc. Nat. Acad. Sci. 104:15 (2007), 6223–6228.
17. [17] Yang, J., Ren, Z., Du, X., Hao, M., Zhou, W., The role of mesenchymal stem/progenitor cells in sarcoma: update and dispute. Stem Cell Invest., 1, 2014, 18.
18. [18] Dick, J.E., Stem cell concepts renew cancer research. Blood 112:13 (2008), 4793–4807.
19. [19] Reya, T., Morrison, S.J., Clarke, M.F., Weissman, I.L., Stem cells, cancer, and cancer stem cells. Nature 414:6859 (2001), 105–111.
20. [20] Nguyen, L.V., Vanner, R., Dirks, P., Eaves, C.J., Cancer stem cells: an evolving concept. Nat. Rev. Cancer 12:2 (2012), 133–143.
21. [21] Xiao, W., Mohseny, A.B., Hogendoorn, P.C.W., Cleton-Jansen, A.-M., Mesenchymal stem cell transformation and sarcoma genesis. Clin. Sarcoma Res., 3(1), 2013, 10.
22. [22] Adhikari, A.S., Agarwal, N., Wood, B.M., Porretta, C., Ruiz, B., Pochampally, R.R., et al. CD117 and Stro-1 identify osteosarcoma tumor-initiating cells associated with metastasis and drug resistance. Cancer Res. 70:11 (2010), 4602–4612.
23. [23] Pajonk, F., Vlashi, E., McBride, W.H., Radiation resistance of cancer stem cells: the 4 R's of radiobiology revisited. Stem Cells 28:4 (2010), 639–648.
24. [24] Dean, M., Fojo, T., Bates, S., Tumour stem cells and drug resistance. Nat. Rev. Cancer 5:4 (2005), 275–284.
25. [25] Gupta, P.B., Chaffer, C.L., Weinberg, R.A., Cancer stem cells: mirage or reality?. Nat. Med. 15:9 (2009), 1010–1012.
26. [26] Meacham, C.E., Morrison, S.J., Tumour heterogeneity and cancer cell plasticity. Nature 501:7467 (2013), 328–337.
27. [27] Standard karyotype of the Norway rat, Rattus norvegicus. Committee for a standardized karyotype of Rattus norvegicus. Cytogenet Cell Genet, 12(3), 1973, pp. 199–205.
28. [28] Courtenay, V.D., Mills, J., An in vitro colony assay for human tumours grown in immune-suppressed mice and treated in vivo with cytotoxic agents. Br. J. Cancer 37:2 (1978), 261–268.
29. [29] Goodell, M.A.R.M., Kim, H., Marks, D.F., DeMaria, M., Paradis, G., Grupp, S.A., Sieff, C.A., Mulligan, R.C., Johnson, R.P., Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species. Nat. Med 3:12 (1997), 1337–1345.
30. [30] Peister, A., Mellad, J.A., Wang, M., Tucker, H.A., Prockop, D.J., Stable transfection of MSCs by electroporation. Gene Ther. 11:2 (2004), 224–228.
31. [31] Van den Berg, E.M.W., Hoekstra, H.J., Kamps, W.A., de Jong, B., DNA ploidy and karyotype in recurrent and metastatic soft tissue sarcomas. Mod. Pathol. 5:5 (1992), 505–514.
32. [32] Cin, P.D., Pauwels, P., Sciot, R., Van Den, Berghe, H., Multiple chromosome rearrangements in a fibrosarcoma. Cancer Genet. Cytogenet. 87:2 (1996), 176–178.
33. [33] Boesch, M., Zeimet, A.G., Reimer, D., Schmidt, S., Gastl, G., Parson, W., et al. The side population of ovarian cancer cells defines a heterogeneous compartment exhibiting stem cell characteristics. Oncotarget 5:16 (2014), 7027–7039.
34. [34] Pastrana, E., Silva-Vargas, V., Doetsch, F., Eyes wide open: a critical review of sphere-formation as an assay for stem cells. Cell. Stem Cell. 8:5 (2011), 486–498.
35. [35] Rappa, G., Mercapide, J., Anzanello, F., Prasmickaite, L., Xi, Y., Ju, J., et al. Growth of cancer cell lines under stem cell-like conditions has the potential to unveil therapeutic targets. Exp. Cell Res. 314:10 (2008), 2110–2122.
36. [36] Hardisty, J.F., Elwell, M.R., Ernst, H., Greaves, P., Kolenda-Roberts, H., Malarkey, D.E., et al. Histopathology Of hemangiosarcomas in mice and hamsters and liposarcomas/fibrosarcomas in rats associated with PPAR agonists. Toxicol. Pathol. 35:7 (2007), 928–941.
37. [37] Miura, M., Miura, Y., Padilla-Nash, H.M., Molinolo, A.A., Fu, B., Patel, V., et al. Accumulated chromosomal instability in murine bone marrow mesenchymal stem cells leads to malignant transformation. Stem Cells 24:4 (2006), 1095–1103.
38. [38] Foudah, D., Redaelli, S., Donzelli, E., Bentivegna, A., Miloso, M., Dalprà, L., Tredici, G., Monitoring the genomic stability of in vitro cultured rat bone-marrow-derived mesenchymal stem cells. Chromosome Res. 17:8 (2009), 1025–1039.
39. [39] Torres, E.M., Dephoure, N., Panneerselvam, A., Tucker, C.M., Whittaker, C.A., Gygi, S.P., Dunham, M.J., Amon, A., Identification of aneuploidy-tolerating mutations. Cell 143:1 (2010 1), 71–83.
40. [40] D'Angelo, S.P., Tap, W.D., Schwartz, G.K., Carvajal, R.D., Sarcoma immunotherapy: past approaches and future directions. Sarcoma, 2014, 391967.
41. [41] Balkwill, F.R., Capasso, M., Hagemann, T., The tumor microenvironment at a glance. J. Cell Sci. 125:23 (2012), 5591–5596.